title: Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis.
abstract: Our previous study found copy number variation of chromosome fragment 5p13.1-13.3 might involve in the progression of ovarian cancer. In the current study, the alteration was validated and complement component 7 (C7), located on 5p13.1, was identified. To further explore the clinical value of C7 in tumors, 156 malignant, 22 borderline, 33 benign and 24 normal ovarian tissues, as well as 173 non-small cell lung cancer (NSCLC) tissues along with corresponding adjacent and normal tissues from the tissue bank of Zhejiang Cancer Hospital were collected. The expression of C7 was analyzed using reverse transcriptase quantitative polymerase chain reaction. As a result, the C7 expression displayed a gradual downward trend in normal, benign, borderline and malignant ovarian tissues, and the decreased expression of C7 was correlative to poor differentiation in patients with ovarian cancer. Interestingly, a similar change of expression of C7 was found in normal, adjacent and malignant tissues in patients with NSCLC, and low expression of C7 was associated with worse grade and advanced clinical stage. Both results from this cohort and the public database indicated that NSCLC patients with low expression of C7 had a worse outcome. Furthermore, multivariate cox regression analysis showed NSCLC patients with low C7 had a 3.09 or 5.65-fold higher risk for relapse or death than those with high C7 respectively, suggesting C7 was an independent prognostic predictor for prognoses of patients with NSCLC. Additionally, overexpression of C7 inhibited colony formation of NSCLC cells, which hints C7 might be a potential tumor suppressor.
authors.affiliation: Laboratory of Cancer Biology, Provincial Key Lab of Biotherapy in Zhejiang, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.|Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Lisha
authors.initials: L
authors.lastname: Ying
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Fanrong
authors.initials: F
authors.lastname: Zhang
authors.affiliation: Tissue Bank of Zhejiang Cancer Hospital, Hangzhou, China.
authors.forename: Xiaodan
authors.initials: X
authors.lastname: Pan
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Kaiyan
authors.initials: K
authors.lastname: Chen
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Zhang
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Jiaoyue
authors.initials: J
authors.lastname: Jin
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Junzhou
authors.initials: J
authors.lastname: Wu
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Jianguo
authors.initials: J
authors.lastname: Feng
authors.affiliation: Cancer Epidemiology Program, University of Hawaii Cancer Center, Hawaii, USA.
authors.forename: Herbert
authors.initials: H
authors.lastname: Yu
authors.affiliation: Laboratory of Cancer Biology, Provincial Key Lab of Biotherapy in Zhejiang, Sir Runrun Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
authors.forename: Hongchuan
authors.initials: H
authors.lastname: Jin
authors.affiliation: Cancer Research Institute, Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Su
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000401:mortality; D045744:Cell Line, Tumor; D003184:Complement C7 / Q000502:physiology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D025521:Tumor Suppressor Proteins / Q000502:physiology*
chemical_list: D003184:Complement C7; D025521:Tumor Suppressor Proteins
keywords: complement component 7; non-small cell lung cancer; ovarian cancer; prognosis; tumor progression